title: Antithrombotic properties of a dermatan sulfate hexadecasaccharide fractionated by affinity for heparin cofactor II.
abstract: The relationship between the antithrombotic activity of dermatan sulfate (DS) in vivo and its catalytic effect on the inhibition of thrombin by heparin cofactor II (HC II) in vitro was investigated. DS was depolymerized by Smith degradation and the fragments obtained were separated by gel filtration. The fragment of minimal size with full catalytic activity was a hexadecasaccharide, which was further fractionated by affinity for immobilized HC II. Only a small proportion by weight (6.7%) was recovered in the high-affinity fraction, which had about 10 times more catalytic activity than the unfractionated oligosaccharide; the change in activity was primarily caused by the removal of inert materials, recovered in the low-affinity fraction. 1H-NMR spectra indicated strengthening of the signal given by Ido A (2S04) in the high-affinity fraction compared with that of the low-affinity fraction. The anticoagulant activity of the high-affinity fraction was exclusively HC II-dependent. The antithrombotic potency was evaluated in rabbits using the Wessler-thromboplastin model. Half-maximal prevention of thrombosis was obtained after injection of 250 micrograms/kg DS, of 500 micrograms/kg hexadecasaccharide, or of 60 micrograms/kg of its high-affinity fraction. The low-affinity fraction was ineffective at the highest dose tested (1,200 micrograms/kg) and did not potentiate the effect of the high-affinity fraction. These results show that the antithrombotic effect of DS is essentially dependent on HC II binding and activation and that HC II is therefore a suitable target for antithrombotic drugs.
authors: Laboratoire d'Hémostase, Centre de Transfusion Sanguine CHU Purpan, Toulouse, France.
authors: P
authors: P
authors: Sie
authors: D
authors: D
authors: Dupouy
authors: C
authors: C
authors: Caranobe
authors: M
authors: M
authors: Petitou
authors: B
authors: B
authors: Boneu
mesh_terms: D000818:Animals; D000925:Anticoagulants / Q000494:pharmacology; D005591:Chemical Fractionation; D002846:Chromatography, Affinity; D003871:Dermatan Sulfate / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D015844:Heparin Cofactor II / Q000737:chemistry*; D006801:Humans; D007275:Injections, Intravenous; D009682:Magnetic Resonance Spectroscopy; D008297:Male; D009844:Oligosaccharides / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D011817:Rabbits
chemical_list: D000925:Anticoagulants; D005343:Fibrinolytic Agents; D009844:Oligosaccharides; D003871:Dermatan Sulfate; D015844:Heparin Cofactor II